175 related articles for article (PubMed ID: 37432068)
1. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials.
Shimony S; Flamand Y; Valtis YK; Place AE; Silverman LB; Vrooman LM; Brunner AM; Sallan SE; Stone RM; Wadleigh M; Neuberg DS; DeAngelo DJ; Luskin MR
Blood Adv; 2023 Sep; 7(18):5234-5245. PubMed ID: 37432068
[TBL] [Abstract][Full Text] [Related]
2. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials.
Valtis YK; Stevenson KE; Place AE; Silverman LB; Vrooman LM; Gotti G; Brunner AM; Nauffal M; DeAngelo DJ; Luskin MR
Blood Adv; 2022 Jan; 6(1):72-81. PubMed ID: 34610104
[TBL] [Abstract][Full Text] [Related]
3. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
[TBL] [Abstract][Full Text] [Related]
4. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
5. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
Valtis YK; Flamand Y; Shimony S; Place AE; Silverman LB; Vrooman LM; Brunner AM; Sallan SE; Wadleigh M; Stone RM; DeAngelo DJ; Luskin MR
Leukemia; 2024 Mar; 38(3):482-490. PubMed ID: 38177437
[TBL] [Abstract][Full Text] [Related]
6. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
Stock W; La M; Sanford B; Bloomfield CD; Vardiman JW; Gaynon P; Larson RA; Nachman J; ;
Blood; 2008 Sep; 112(5):1646-54. PubMed ID: 18502832
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience.
Elashtokhy HEA; Elgohary HE; Eldeep BB; Gaber SM; Elbedewy TA
J Egypt Natl Canc Inst; 2021 Apr; 33(1):9. PubMed ID: 33826046
[TBL] [Abstract][Full Text] [Related]
8. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.
Kahn JM; Cole PD; Blonquist TM; Stevenson K; Jin Z; Barrera S; Davila R; Roberts E; Neuberg DS; Athale UH; Clavell LA; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Sallan SE; Silverman LB; Kelly KM
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090520
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia.
Nasir SS; Giri S; Nunnery S; Martin MG
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):126-132.e1. PubMed ID: 27836483
[TBL] [Abstract][Full Text] [Related]
10. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
[TBL] [Abstract][Full Text] [Related]
11. Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes.
Lalayanni C; Demosthenous C; Iskas M; Kelaidi C; Papathanasiou M; Syrigou A; Athanasiadou A; Papalexandri A; Batsis I; Vardi A; Polychronopoulou S; Sakellari I
Leuk Lymphoma; 2022 Dec; 63(13):3128-3137. PubMed ID: 36002396
[TBL] [Abstract][Full Text] [Related]
12. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.
Hayashi H; Volt F; Sanz J; Petersen E; Dhedin N; Hough R; Milpied N; Angelucci E; Yakoub-Agha I; Michallet M; Michel G; Aljurf M; Kenzey C; Rocha V; Dalle JH; Bader P; Ruggeri A; Gluckman E;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2438-2446. PubMed ID: 31394275
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Henderson TO; Parsons SK; Wroblewski KE; Chen L; Hong F; Smith SM; McNeer JL; Advani RH; Gascoyne RD; Constine LS; Horning S; Bartlett NL; Shah B; Connors JM; Leonard JI; Kahl BS; Kelly KM; Schwartz CL; Li H; Friedberg JW; Friedman DL; Gordon LI; Evens AM
Cancer; 2018 Jan; 124(1):136-144. PubMed ID: 28902390
[TBL] [Abstract][Full Text] [Related]
15. Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment.
Janardan SK; Miller TP
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):581-586. PubMed ID: 38066874
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trial Enrollment Among Adolescent and Young Adults with Primary Central Nervous System Tumors Treated at the Dana-Farber Cancer Institute.
Sarvode S; Vogelzang JR; Sarvode Mothi S; Warren KE; Reardon DA; Yeo KK
J Adolesc Young Adult Oncol; 2022 Dec; 11(6):543-549. PubMed ID: 35049364
[No Abstract] [Full Text] [Related]
17. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
Silverman LB; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Arkin S; Declerck L; Cohen HJ; Sallan SE
Blood; 2001 Mar; 97(5):1211-8. PubMed ID: 11222362
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center.
Jaime-Pérez JC; Padilla-Medina JR; Fernández LT; Herrera-Garza JL; Gutiérrez-Aguirre CH; Tarín-Arzaga L; Gómez-Almaguer D
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):286-292. PubMed ID: 29478946
[TBL] [Abstract][Full Text] [Related]
19. Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study.
Muffly L; Alvarez E; Lichtensztajn D; Abrahão R; Gomez SL; Keegan T
Blood Adv; 2018 Apr; 2(8):895-903. PubMed ID: 29669756
[TBL] [Abstract][Full Text] [Related]
20. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.
Siegel SE; Stock W; Johnson RH; Advani A; Muffly L; Douer D; Reed D; Lewis M; Freyer DR; Shah B; Luger S; Hayes-Lattin B; Jaboin JJ; Coccia PF; DeAngelo DJ; Seibel N; Bleyer A
JAMA Oncol; 2018 May; 4(5):725-734. PubMed ID: 29450465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
